127 related articles for article (PubMed ID: 15458371)
1. Lung cancer-related genes in the blood.
Sonobe M; Tanaka F; Wada H
Ann Thorac Cardiovasc Surg; 2004 Aug; 10(4):213-7. PubMed ID: 15458371
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?
Bremnes RM; Sirera R; Camps C
Lung Cancer; 2005 Jul; 49(1):1-12. PubMed ID: 15949585
[TBL] [Abstract][Full Text] [Related]
3. Circulating DNA and lung cancer.
Xue X; Zhu YM; Woll PJ
Ann N Y Acad Sci; 2006 Sep; 1075():154-64. PubMed ID: 17108206
[TBL] [Abstract][Full Text] [Related]
4. Circulating free tumor DNA and colorectal cancer.
Lecomte T; Ceze N; Dorval E; Laurent-Puig P
Gastroenterol Clin Biol; 2010 Dec; 34(12):662-81. PubMed ID: 20832215
[TBL] [Abstract][Full Text] [Related]
5. Microsatellite analysis of induced sputum DNA in patients with lung cancer in heavy smokers and in healthy subjects.
Castagnaro A; Marangio E; Verduri A; Chetta A; D'Ippolito R; Del Donno M; Olivieri D; Di Cola G
Exp Lung Res; 2007 Aug; 33(6):289-301. PubMed ID: 17694439
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes.
Sher YP; Shih JY; Yang PC; Roffler SR; Chu YW; Wu CW; Yu CL; Peck K
Clin Cancer Res; 2005 Jan; 11(1):173-9. PubMed ID: 15671543
[TBL] [Abstract][Full Text] [Related]
7. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
[TBL] [Abstract][Full Text] [Related]
8. The early detection of occult lung cancer.
Tockman MS; Mulshine JL
Chest Surg Clin N Am; 2000 Nov; 10(4):737-49. PubMed ID: 11091923
[TBL] [Abstract][Full Text] [Related]
9. Molecular diagnostic markers for lung cancer in sputum and plasma.
Wang YC; Hsu HS; Chen TP; Chen JT
Ann N Y Acad Sci; 2006 Sep; 1075():179-84. PubMed ID: 17108209
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
[TBL] [Abstract][Full Text] [Related]
11. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer.
Grote HJ; Schmiemann V; Geddert H; Bocking A; Kappes R; Gabbert HE; Sarbia M
Cancer; 2006 Apr; 108(2):129-34. PubMed ID: 16444703
[TBL] [Abstract][Full Text] [Related]
12. Free circulating nucleic acids in plasma and serum (CNAPS) -- Useful for the detection of lung cancer patients?
Fleischhacker M; Schmidt B
Cancer Biomark; 2010; 6(3-4):211-9. PubMed ID: 20660966
[TBL] [Abstract][Full Text] [Related]
13. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3.
Tan SH; Ida H; Lau QC; Goh BC; Chieng WS; Loh M; Ito Y
Oncol Rep; 2007 Nov; 18(5):1225-30. PubMed ID: 17914577
[TBL] [Abstract][Full Text] [Related]
14. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D
J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165
[TBL] [Abstract][Full Text] [Related]
15. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer.
Ito M; Ito G; Kondo M; Uchiyama M; Fukui T; Mori S; Yoshioka H; Ueda Y; Shimokata K; Sekido Y
Cancer Lett; 2005 Jul; 225(1):131-9. PubMed ID: 15922865
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer.
Hsu HS; Wen CK; Tang YA; Lin RK; Li WY; Hsu WH; Wang YC
Clin Cancer Res; 2005 Aug; 11(15):5410-6. PubMed ID: 16061855
[TBL] [Abstract][Full Text] [Related]
17. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.
Paci M; Maramotti S; Bellesia E; Formisano D; Albertazzi L; Ricchetti T; Ferrari G; Annessi V; Lasagni D; Carbonelli C; De Franco S; Brini M; Sgarbi G; Lodi R
Lung Cancer; 2009 Apr; 64(1):92-7. PubMed ID: 18804892
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer patients.
Taback B; Saha S; Hoon DS
Ann N Y Acad Sci; 2006 Sep; 1075():197-203. PubMed ID: 17108212
[TBL] [Abstract][Full Text] [Related]
19. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
Kim YT; Lee SH; Sung SW; Kim JH
Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
[TBL] [Abstract][Full Text] [Related]
20. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
